The aim of the study is to examine the bone metastasis of breast cancer administrated Zoledronic acid.Materials and methods
One hundred and thirty-three breast cancer patients who received Zoledronic acid therapy from May, 2006 till Nov,2011.They include recurrence case after operation and stage IV at first examination. Classify the symptom(+) group and the symptom(−) group which distinguish an existence of symptom at the time of Zoledronic acid therapy began. And compare the OS, OS after recurrence and dulation of morphine dosing periods. Severe adverse event, the tendency of Bisphosphonate-related osteonecrosis of the jaw, was examined.Result
The symptom(+) group 40 case, the symptom(−) group 94 case, there is no difference about the pathological feature. There is no difference between two groups about OS (log rank:P = 0.47), but statistical predominance was seen [symptom(−) group median 53.2 ± 6.2 (95% CI: 41.1–65.4 and symptom(+) group median 35.1 ± 4.0 (95% CI: 27.2–42.9, P = 0.0007). And as the symptom(−) group, statistical predominance was seen compare with the symptom(+) group about dulation of morphine dosing periods (median 15.5 ± 4.2, 95% CI: 7.2–23.7 versus 30.0 ± 3.1, 95% CI: 23.8–36.2).Conclusion
The possibility of the extend of OS after recurrence, the shortening of the periods of beginning of morphine dosing periods were suggested.